Rani Therapeutics Holdings, Inc.RANINASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank17
3Y CAGR-15.5%
5Y CAGR+12.9%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-15.5%/yr
Annual compound
5Y CAGR
+12.9%/yr
Recent deceleration
Percentile
P17
Within normal range
vs 5Y Ago
1.8x
Solid growth
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$22.11M-17.2%
2024$26.68M-32.7%
2023$39.62M+8.2%
2022$36.61M+38.2%
2021$26.48M+119.9%
2020$12.04M-51.0%
2019$24.58M-